Igf-1 lr3

Mechanism of action

It binds primarily to the IGF-1 receptor (IGF-1R), activating intracellular signaling pathways such as PI3K-AKT-mTOR (protein anabolism, cell survival, metabolism) and RAS-RAF-MEK-ERK (proliferation and differentiation). Reduced binding to IGFBPs increases the proportion of biologically available peptide. Activation of these pathways may promote protein synthesis and cell growth, but also increase mitogenic and anti-apoptotic signaling, which is relevant to safety (e.g., the theoretical risk of promoting pre-existing neoplastic clones).

Supported benefits

• Increased cell proliferation and differentiation in in vitro models (e.g., myoblasts) and animal models, with enhanced anabolic signaling (strong)
• Anabolic effects on muscle tissues in preclinical models (dependent on dose, nutritional context, and hormonal status) (moderate)
• Improvement in some tissue recovery/regeneration parameters in experimental models (wounds, specific tissues), not generalizable to humans (limited)
• Improvement in performance or body composition in healthy humans specifically with IGF-1 LR3 (limited)

Safety & side effects

• Hypoglycemia (potentially severe), with symptoms such as sweating, tremors, confusion, weakness, syncope
• Edema/fluid retention, possible increase in blood pressure in predisposed individuals
• Headache, nausea, dizziness (reported with modulation of the IGF/insulin axis in general)
• Pain/irritation at the administration site (if parenteral)
• Possible alteration of insulin sensitivity and carbohydrate/lipid metabolism
• Potential unwanted tissue growth (mitogenic effects), including theoretical concern regarding the promotion of pre-neoplastic lesions

FAQ

Is IGF-1 LR3 the same as natural IGF-1?

No. It is a synthetic analogue of IGF-1 with structural modifications (Arg3 and N-terminal extension) that alter its binding to IGFBPs, stability, and duration of action, making its effects not directly equivalent to endogenous IGF-1.

Why is it considered risky from an oncological perspective?

Activation of IGF-1R stimulates pro-growth and anti-apoptotic pathways (PI3K-AKT and MAPK). In the presence of cells with pre-existing alterations, an increase in IGF signaling may theoretically favor cell proliferation and survival. This does not prove clinical causality for LR3, but it justifies a high degree of caution.

What is the main acute risk?

Hypoglycemia, because IGF signaling can have insulin-like effects on glucose metabolism. The risk increases with high insulin sensitivity, fasting, physical activity, and co-use of glucose-lowering agents.

Are there standardized and approved human dosages?

No. There is no approved and robustly validated clinical range for IGF-1 LR3 in humans. Much of the data is preclinical or anecdotal and does not allow for safe recommendations.

Is it detectable or relevant for anti-doping?

Growth factors and their analogues are typically prohibited in sports. Detection methods may include direct/indirect approaches depending on the substance and the regulatory context.